Oxford BioMedica Announces Initiation of Second CART Programme for Major Pharmaceutical Company
Oxford, UK – 29 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces today that the Group has initiated work on a second Chimeric Antigen Receptor T cell… Read More
Oxford BioMedica Announces Successful MHRA Inspection and Approval to Manufacture at its new Facility in Yarnton, Oxford
– New manufacturing facility fully operational – Creates extra capacity for wholly-owned pipeline, Novartis partnership and other new potential customers… Read More
Board change
Oxford, UK – 5 January 2016: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces that Dan Soland has been required to step down as a Non-Executive Director, due to… Read More
Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016.
From 2008 to 2014 Dr.Tallarigo was a member of the Board, and Chairman from 2011, of Intercept Pharmaceuticals (Nasdaq:ICPT). Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat liver… Read More
Business Update
Oxford, UK – 4 November 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, is pleased to announce the following business update. Read More
GSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents
Oxford, UK – 28 October 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces that GlaxoSmithKline PLC (GSK) has exercised an option to obtain a non-exclusive licence for two… Read More
INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2015
Oxford, UK – 27 August 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, today announces interim results for the six months ended 30 June 2015. Read More
Oxford BioMedica: Notice of Interim Results Results date: 27 August 2015
Oxford, UK – 6 August 2015: Oxford BioMedica plc (LSE:OXB), (“Oxford Biomedica” or “the Group”) a leading gene and cell therapy group, will be announcing its interim results for the six months ended 30 June 2015 on Thursday 27 August 2015… Read More
Oxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London
Oxford, UK – 23 June 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, announces that Chief Executive Officer John Dawson will present today at the 2015 JMP Securities Life… Read More
Oxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York
Oxford, UK – 29 May 2015: Oxford BioMedica plc (LSE:OXB) (“the Group”), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer of Oxford BioMedica, is scheduled to present at the Jefferies 2015… Read More
Oxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board
London, UK – 7 May 2015: Oxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE:OXB), a leading gene and cell therapy group, today announces the appointment of Daniel Soland as a Non-Executive Director of the Group. Read More